Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its Board of Directors has appointed Thomas W. Ross, Sr. as its lead independent director. Mr. Ross, who has been a member of Valeant's Board since March 8, 2016, serves on the Board's Nominating and Corporate Governance Committee and is Chairperson of its Conduct and Compliance Committee.

15.06.2016, 15:36

Medicines production

Abbott will announce its second-quarter 2016 financial results

Acerus Announces Voting Results for 2016 AGM

AS "Olainfarm" will close the list of shareholders for dividend payments on June 21, 2016

Valeant Canada is expanding its Canadian manufacturing

Takeda Announces Support to JVOAD

Pfizer Inc. today broke ground for its new biologics clinical manufacturing facility in Andover

Takeda and M2Gen Collaborate with ORIEN

Varian Medical Systems announced it has been selected by the Icon Group to provide 10 TrueBeam® medical linear accelerators

Baxter International is committed to enhancing patient safety during medication delivery

Bausch + Lomb launched new PreserVision® AREDS 2 Formula + Multivitamin

Sagent Pharmaceuticals announces that it has entered into a definitive agreement with Teva Pharmaceutical Industries and Actavis LLC

Civil Society Initiative Subsidy Program Takeda Well-Being Program II

Merck announced that researchers are scheduled to provide more than 30 scientific data presentations

Valeant Pharmaceuticals announced that its Board of Directors has appointed Thomas W. Ross

Carbylan Therapeutics, Inc. and KalVista Pharmaceuticals Ltd. Enter into Share Purchase Agreement

Комментарии

All news in one column

News archive for the month

декабрь, 2025